Pharmacokinetic Study of Sirolimus-Eluting BioResorbable Vascular Scaffold System for Treatment of Native Coronary Lesions: A Sub-Study of MeRes-1 Trial.
Journal:
Cardiology research
Published Date:
Dec 7, 2018
Abstract
BACKGROUND: MeRes100™ (Meril Life Sciences Pvt. Ltd., Vapi, India) is a novel sirolimus-eluting bioresorbable vascular scaffold (BRS). The purpose of this sub-study of MeRes-1 trial is to evaluate the systemic release of sirolimus from MeRes100 BRS implanted for the treatment of native coronary artery lesions.
Authors
Keywords
No keywords available for this article.